Skip to main content
2025 ASCRS Annual Scientific Meeting Main banner
Final Program


Visit ASCRS U
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Self-Assessment
Self-Assessment
Social
Social
Industry
Industry
Back

Session: ePoster: Colon and Colorectal Cancer 1 (Sun8)

EP257 - Evaluating the Benefits of Tegafur-Uracil Adjuvant Therapy in Low-Risk Stage IIa Colon Cancer: Insights from a Decade-Long Study

Sunday, May 11, 2025
8:43 AM – 8:48 AM PT
Location: Monitor 4, Sails Pavilion, Upper Level

    ePoster Presenter(s)

  • Chang Lin Lin

    Attending physician
    colorectal surgery
    Taichung, Taichung, Taiwan (Republic of China)

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

All of the relevant financial relationships listed below have been mitigated.
Chang Lin Lin: This individual has no financial relationships with ineligible companies.
Image or Table (Do Not add text here):

Purpose/Background: Surgical resection is the gold standard for treating non-metastatic colorectal cancer (CRC). Previous real-world data have shown that the five-year overall survival (OS) for Stage IIIa patients is longer than that for Stage IIa patients, highlighting the importance of adjuvant therapy (ACT) for Stage IIa. This study aims to evaluate the treatment outcomes and prognostic factors for Stage IIa colon cancer at our hospital over the past decade.

Methods/Interventions: This retrospective study was conducted at a medical center and included patients treated between January 1, 2010, and December 31, 2019. We included only patients who underwent surgery and had pathological Stage IIa or Stage IIIa colon cancer. Data collected included patient characteristics, oncological outcomes, receipt of adjuvant therapy, and adverse effects associated with adjuvant therapy.

Results/Outcomes: The five-year OS for Stage IIIa patients was higher than for Stage IIa patients, but the difference was not statistically significant. The Tegafur-Uracil (UFT) group had longer five-year progression-free survival (PFS) and five-year overall survival (OS) compared to the No ACT group (P < 0.005). The Receiver Operating Characteristic (ROC) curve identified the optimal cut-off point for UFT duration as ≤1.74 years, with the area under the curve (AUC) being statistically significant (p = 0.05).

Conclusion/Discussion: ACT is recommended even for low-risk Stage IIa patients postoperatively. The adverse effects of UFT were generally acceptable, with Grade 3 or higher adverse effects being rare. If UFT is used as an ACT regimen for stage IIa colon cancer, a duration of more than one year is suggested.